Overview

Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis

Status:
NOT_YET_RECRUITING

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

Sepsis is a common and life-threatening condition caused by a dysregulated host immune response to infection. Given the prominent role of endothelial breakdown and dysfunction in sepsis, therefore, there is an urgent need to establish strategies to protect the endothelium and preserve microcirculatory function. This study is a randomised clinical study investigating intravenous fluid therapy and oral imatinib therapy in healthy human volunteers exposed to intravenous lipopolysaccharide (LPS). The objective of the study is to investigate the biological effects of fluid and imatinib therapy on LPS-induced microcirculatory dysfunction.

Phase:

PHASE1

Details

Lead Sponsor:

Belfast Health and Social Care Trust

Collaborators:

Medical Research Council
The Royal College of Anaesthetists

Treatments:

Imatinib Mesylate
Ringer's Lactate